dc.contributor.author
Moreno, D. F.
dc.contributor.author
Fernández de Larrea Rodríguez, Carlos José
dc.date.issued
2024-02-06T11:44:08Z
dc.date.issued
2024-06-27T05:10:13Z
dc.date.issued
2023-08-01
dc.date.issued
2024-02-06T10:14:44Z
dc.identifier
https://hdl.handle.net/2445/207222
dc.description.abstract
With the increasing availability of sequencing techniques and new polymerase chain reaction-based methods, data regarding the genomic profile of Waldenström macroglobulinemia (WM) are being continuously analyzed and reproduced. MYD88 and CXCR4 mutations are highly prevalent in all the stages of WM, including the early IgM monoclonal gammopathy of undetermined significance or a more advanced stage, such as smoldering WM. Thus, there is a need to define genotypes before starting either standard treatment regimens or clinical trials. Here, we review the genomic profile of WM and its clinical implications while focusing on recent advances.Copyright © 2023 Elsevier Inc. All rights reserved.
dc.format
application/pdf
dc.relation
Reproducció del document publicat a: https://doi.org/10.1016/j.hoc.2023.04.002
dc.relation
Hematology-Oncology Clinics Of North America, 2023, vol. 37, num. 4, p. 659-670
dc.relation
https://doi.org/10.1016/j.hoc.2023.04.002
dc.rights
cc by-nc-nd (c) Elsevier, 2024
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.subject
Mutació (Biologia)
dc.subject
Mutation (Biology)
dc.title
Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
